PAM
ACOR

Princeton Alpha Management’s Acorda Therapeutics ACOR Stock Holding History

Princeton Alpha Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-80
Closed -$246K – 988
2016
Q2 		$246K Sell
80
-13
-14% -$42.3K 0.04% 602
2016
Q1 		$296K Buy
+93
New +$386K 0.05% 528
2015
Q4 		– Sell
-67
Closed -$214K – 966
2015
Q3 		$214K Buy
+67
New +$260K 0.04% 587

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Princeton Alpha Management's ACOR Position: Q3 2016 in Review

Princeton Alpha Management sold out of Acorda Therapeutics (ACOR) in Q3 2016, closing a stake of 80 shares — an estimated $246K sold.

Princeton Alpha Management first reported a position in ACOR in Q3 2015 and held it in 3 quarters. The position peaked at $296K in Q1 2016. 167 funds tracked by Wall St. Rank hold ACOR as of Q3 2016.

  • Princeton Alpha Management reported no remaining Acorda Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Princeton Alpha Management sold 80 Acorda Therapeutics shares in Q3 2016, an estimated $246K.
  • Princeton Alpha Management first reported a position in Acorda Therapeutics in Q3 2015 and held it in 3 quarters.
  • Princeton Alpha Management's Acorda Therapeutics position peaked at $296K in Q1 2016.
  • 167 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2016.

Based on Princeton Alpha Management's 13F filing for Q3 2016, filed 10 Nov 2016.